CONTEXT: Vitamin D deficiency is associated with many adverse health outcomes, yet little is known about the genetic epidemiology of vitamin D or its metabolites. OBJECTIVE: Our objective was to examine the relationship among three vitamin D-related genes and levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] in Hispanics (HAs) and African Americans (AAs). DESIGN AND SETTING: The cross-sectional Insulin Resistance Atherosclerosis Family Study recruited and examined subjects in: Los Angeles, California (AAs; 513 individuals from 42 families); San Luis Valley (SLV), Colorado (HAs; 513 individuals from 30 families); and San Antonio (SA), Texas (HAs; 504 individuals from 58 families). MAIN OUTCOME MEASURES: Plasma levels of 25(OH)D and 1,25(OH)2D were measured. RESULTS: Levels of 25(OH)D were highest in SLV-HAs [18.3 +/- 7.7 ng/ml (45.7 +/- 19.2 nmol/liter)], lower in SA-HAs [14.6 +/- 6.4 ng/ml (36.4 +/- 16.0 nmol/liter)], and lowest in AAs [11.0 +/- 5.4 ng/ml (27.5 +/- 13.5 nmol/liter)]. Levels of 1,25(OH)2D were similar in AAs [43.5 +/- 13.9 pg/ml (113.1 +/- 36.1 pmol/liter)] and SLV-HAs [43.2 +/- 13.3 pg/ml (112.3 +/- 34.6 pmol/liter)], but higher in SA-HAs [48.6 +/- 17.0 pg/ml (126.4 +/- 44.2 pmol/liter)]. After adjusting for gender and age within the site, two single nucleotide polymorphisms (SNPs) in the vitamin D binding protein gene (DBP), rs4588 and rs7041, were associated with 25(OH)D, and one SNP in the DBP, rs4588, was associated with 1,25(OH)2D at all three study centers. CONCLUSIONS: SNPs in the DBP are associated with levels of 25(OH)D and 1,25(OH)2D in HA and AA participants in the Insulin Resistance Atherosclerosis Family Study.
CONTEXT: Vitamin D deficiency is associated with many adverse health outcomes, yet little is known about the genetic epidemiology of vitamin D or its metabolites. OBJECTIVE: Our objective was to examine the relationship among three vitamin D-related genes and levels of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] in Hispanics (HAs) and African Americans (AAs). DESIGN AND SETTING: The cross-sectional Insulin Resistance Atherosclerosis Family Study recruited and examined subjects in: Los Angeles, California (AAs; 513 individuals from 42 families); San Luis Valley (SLV), Colorado (HAs; 513 individuals from 30 families); and San Antonio (SA), Texas (HAs; 504 individuals from 58 families). MAIN OUTCOME MEASURES: Plasma levels of 25(OH)D and 1,25(OH)2D were measured. RESULTS: Levels of 25(OH)D were highest in SLV-HAs [18.3 +/- 7.7 ng/ml (45.7 +/- 19.2 nmol/liter)], lower in SA-HAs [14.6 +/- 6.4 ng/ml (36.4 +/- 16.0 nmol/liter)], and lowest in AAs [11.0 +/- 5.4 ng/ml (27.5 +/- 13.5 nmol/liter)]. Levels of 1,25(OH)2D were similar in AAs [43.5 +/- 13.9 pg/ml (113.1 +/- 36.1 pmol/liter)] and SLV-HAs [43.2 +/- 13.3 pg/ml (112.3 +/- 34.6 pmol/liter)], but higher in SA-HAs [48.6 +/- 17.0 pg/ml (126.4 +/- 44.2 pmol/liter)]. After adjusting for gender and age within the site, two single nucleotide polymorphisms (SNPs) in the vitamin D binding protein gene (DBP), rs4588 and rs7041, were associated with 25(OH)D, and one SNP in the DBP, rs4588, was associated with 1,25(OH)2D at all three study centers. CONCLUSIONS: SNPs in the DBP are associated with levels of 25(OH)D and 1,25(OH)2D in HA and AA participants in the Insulin Resistance Atherosclerosis Family Study.
Authors: M Parisien; F Cosman; D Morgan; M Schnitzer; X Liang; J Nieves; L Forese; M Luckey; D Meier; V Shen; R Lindsay; D W Dempster Journal: J Bone Miner Res Date: 1997-06 Impact factor: 6.741
Authors: Leora Henkin; Richard N Bergman; Donald W Bowden; Darrell L Ellsworth; Steven M Haffner; Carl D Langefeld; Braxton D Mitchell; Jill M Norris; Marian Rewers; Mohammed F Saad; Elizabeth Stamm; Lynne E Wagenknecht; Stephen S Rich Journal: Ann Epidemiol Date: 2003-04 Impact factor: 3.797
Authors: S Sidney; D R Jacobs; W L Haskell; M A Armstrong; A Dimicco; A Oberman; P J Savage; M L Slattery; B Sternfeld; L Van Horn Journal: Am J Epidemiol Date: 1991-06-15 Impact factor: 4.897
Authors: André G Uitterlinden; Yue Fang; Joyce B J van Meurs; Hans van Leeuwen; Huibert A P Pols Journal: J Steroid Biochem Mol Biol Date: 2004-05 Impact factor: 4.292
Authors: L E Wagenknecht; E J Mayer; M Rewers; S Haffner; J Selby; G M Borok; L Henkin; G Howard; P J Savage; M F Saad Journal: Ann Epidemiol Date: 1995-11 Impact factor: 3.797
Authors: Kendra A Young; Tasha E Fingerlin; Carl D Langefeld; Carlos Lorenzo; Steven M Haffner; Lynne E Wagenknecht; Jill M Norris Journal: Ethn Dis Date: 2012 Impact factor: 1.847
Authors: Lisa B Signorello; Scott M Williams; Wei Zheng; Jeffrey R Smith; Jirong Long; Qiuyin Cai; Margaret K Hargreaves; Bruce W Hollis; William J Blot Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: Melissa A Kluczynski; Michael J Lamonte; Julie A Mares; Jean Wactawski-Wende; Ashley Wilder Smith; Corinne D Engelman; Christopher A Andrews; Linda G Snetselaar; Gloria E Sarto; Amy E Millen Journal: Ann Epidemiol Date: 2011-03-17 Impact factor: 3.797
Authors: Jenny N Poynter; Elizabeth T Jacobs; Jane C Figueiredo; Won H Lee; David V Conti; Peter T Campbell; A Joan Levine; Paul Limburg; Loic Le Marchand; Michelle Cotterchio; Polly A Newcomb; John D Potter; Mark A Jenkins; John L Hopper; David J Duggan; John A Baron; Robert W Haile Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254
Authors: Elizabeth T Jacobs; Chad Van Pelt; Ryan E Forster; Wasiq Zaidi; Elizabeth A Hibler; Michael A Galligan; Mark R Haussler; Peter W Jurutka Journal: Cancer Res Date: 2013-02-19 Impact factor: 12.701
Authors: Kimberly J Schmitz; Halcyon G Skinner; Leonelo E Bautista; Tasha E Fingerlin; Carl D Langefeld; Pamela J Hicks; Steven M Haffner; Michael Bryer-Ash; Lynne E Wagenknecht; Donald W Bowden; Jill M Norris; Corinne D Engelman Journal: Am J Hypertens Date: 2009-05-14 Impact factor: 2.689